O-Positive Blood Group Is Associated with Prolonged Recurrence-Free Survival Following Pancreatic Neuroendocrine Tumor (PanNET) Curative-Intent Surgical Resection Abstract #2926

Introduction: The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of pancreatic adenocarcinoma is better in patients with blood group O. This has not been extensively explored in PanNET.
Aim(s): Assess the influence of the ABO and Rhesus blood groups on the risk of recurrence following curative-intent PanNET surgical resection.
Materials and methods: All consecutive patients operated on for well-differentiated panNET in an expert center were retrospectively studied. ABO blood group and Rhesus system distributions were compared to that of the French population. The primary endpoint was recurrence-free survival (RFS). The association of clinical and pathological features with RFS were explored using Cox proportional hazard models.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Louis de Mestier

To read results and conclusion, please login ...

Further abstracts you may be interested in

#904 Role of Metformin on Recurrence-Free Survival (RFS) in Neuroendocrine Tumors (NET)
Introduction: Recent data suggest metformin (Met) has antineoplastic properties in different type of cancer. Effects of Met have never been investigated in NET.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Francesca Marciello
#913 A PCR-Based Multigene Transcript Analysis Blood Test Outperforms Chromogranin A in the Detection of Gastrointestinal and Pancreatic Neuroendocrine Tumors and is Unaffected by PPI Use or Hypertension
Introduction: A critical requirement in the management of gut NETs is a blood biomarker test that is sensitive, specific and reproducible.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Professor Irvin M Modlin
Keywords: biomarker, CgA, NET, PCR
#1265 Prognostic Factors for Recurrence of Sporadic Pancreatic Neuroendocrine Tumors After Surgical Resection
Introduction: Pancreatic neuroendocrine tumors (PNET) are rare neoplasms with heterogeneous presentation. The diagnosis of malignancy is often difficult, and then further studies may contribute to improve prognosis criteria.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: PhD Estela Regina Ramos Figueira
#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET
#1703 NeuroEndocrine Tumors of The Ampullary Region: A Rare Challenging Entity
Introduction: NeuroEndocrine Tumors (NETs) of the ampulla of Vater are rare.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: ...none of the above
Presenting Author: Dr Anna Caterina Milanetto